Latest Cambodian News
FLORENCE, VENICE and ROME, Italy, Dec. 16, 2014 /PRNewswire/ —
Italy: the cradle of culture, literature, art, music, science and business.
In the same way IED – Istituto Europeo di Design has developed a rich educational off…
CHENGDU, China, December 16, 2014 /PRNewswire/ — Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded gene…
SEOUL, South Korea, December 16, 2014 /PRNewswire/ —
Scientists from the College of Medicine at the Catholic University of Korea have published newest data on the M2-PK test from a multi-center study of colorectal cancer screening in the journal ‘Gut and Liver’. The results from cancer expert Professor Yong Kim and his colleagues confirm the exceptionally high capability of the M2-PK test, particularly in comparison to the immunological fecal occult blood test (iFOBT), to detect adenomas and colorectal cancer.
(Photo: http://photos.prnewswire.com/prnh/20140215/721009 )
In their study Professor Kim and colleagues investigated the enzymatic biomarker M2-PK with volunteers in patient groups with 139 cases of colorectal cancer and 124 with adenoma, along with a population-based control group of 60 people, making a total of 323 subjects. The sensitivity of the M2-PK test was 92.8% for colorectal cancer and 69.4% for adenomas. In addition, they also compared the results of the M2-PK test with those of an immunological fecal occult blood test (iFOBT). This was clearly inferior to the M2-PK test. The iFOBT detected only 47.5% of the colon cancers and just 12.1% of the adenomas. Consequently, the M2-PK test detected twice as many colorectal cancer cases and nearly six times the number of adenomas than the immunological fecal occult blood test (iFOBT). These scientific results from the University of Korea categorically confirm the capability of the fecal M2-PK test for screening and early detection of colorectal cancer.
The fecal M2-PK test is available as a qualitative rapid test under the name ScheBo® M2-PK Quick™ and as a fully quantitative ELISA stool test.
Source: Kim YC, et al., Gut and Liver, online December 5th, 2014; http://dx.doi.org/10.5009/gnl13457 , http://www.gutnliver.org/ .
Contact: ScheBo® Biotech AG / Tel: +49-(0)641-4996-0 / Fax: +49-(0)641-4996-78 http://www.schebo.com
Picture is available via epa european pressphoto agency ( http://www.epa.eu/ ) and can be downloaded free of charge at: http://www.presseportal.de/pm/28702/schebo-biotech-ag?keygroup=bild
– Environmental impact remains a challenge for diamond industry; grown diamonds represent a long term solution
MOUNTAIN VIEW, California, Dec. 16, 2014 /PRNewswire/ — Environmental impact generated by diamonds is starting to play a key role in the decision making process by both consumers and trade members. Years of research and technological advancements now offer the diamond industry a new choice of rough diamonds grown above the earth which is both eco-friendly and human friendly. Moreover, these cultured or grown diamonds offer a source of sustainable raw material for the industry in the long term with negligible environmental impact.
New analysis from Frost & Sullivan, Environmental Impact Analysis – Production of Rough Diamonds based on a study comparing the environmental impact of grown diamonds and mined diamonds, depicts that growing diamonds cause significantly less environmental impact as compared to mining diamonds. There are several aspects of environmental impact such as air pollution, water usage, energy usage, etc. There is also a significant level of human impact as well in the process of diamond production. This report quantifies and compares each of these aspects for grown and mined diamonds per carat of diamond produced.
The study compares nine parameters encompassing environmental and human impact. There is also an overall benchmarking done on a ratio scale as well as on a combined scale revealing a total environmental impact rating
Frost & Sullivan’s environmental impact study indicates that the scale of difference in impact of mined and grown diamonds is very large. The Chemical Vapor Deposition (CVD) process used to grow diamonds is a cleaner process with a significantly lower environmental impact as compared to mining. Moreover, on the human impact front, diamond growing process necessitates maintaining a clean room environment and has no life or occupational hazards to their employees.
Some of the key areas of concern for mined diamonds continue to be air emissions and waste generation in the mining process. However, there are a number of sustainability initiatives that are being carried out by mined diamond producers focused on people, environment and economy. Such initiatives include funding local hospitals, running programs to counter HIV and AIDS, protecting biodiversity in the region, etc. Most of these initiatives are long term in nature and are targeted at benefiting the region of operation in a more sustainable manner.
While mined diamond industry continues to pump in time and resources to control and reverse the environmental damage, the scale of impact generated is too significant to be ignored. Also, in some cases restoring the environment to a state of no impact is highly improbable, especially if the impact is continuous rather than one time. Moreover, there are issues in ascertaining the extent of the impact as well as they may not be recorded or tracked due to differing laws and regulations across countries. The impact generated by mining continues even after the diamond production from a mine ceases.
On the human impact side, the extent of hazards in diamond mining is quite intense ranging from mine explosions trapping miners and equipment accidents, to workplace induced illnesses such as tuberculosis, permanent hearing loss, slow poisoning and increased cancer risk. However, the nature of this impact is quite visible and is under constant focus and monitoring by the companies in the mined diamond industry as they continue to strive for zero harm.
However, for grown diamond industry, challenges in tracking are minimal as the process of growth happens in a “greenhouse” setup that is easy to track, monitor and control in terms of environmental, social or any other kind of impact.
Sustainability in the diamond industry will continue to be a key concern as it will impact both the environment as well as buying patterns of consumers. From a supply perspective, cultured or grown diamonds offer an option to cater to the new consumer segment looking for an eco and human friendly product.
The report may be downloaded through registering at this link: https://www.frost.com/sublib/display-market-insight.do?id=293005646
For media queries or if you are interested in more information on this study, please send an email to ariel.brown@frost.com.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.
Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Subscribe: Newsletter on “the next big thing”
Register: Gain access to visionary innovation
Contact:
Ariel Brown
Corporate Communications – North America
P: +1-210-247-2481
F: +1-210-348-1003
E: ariel.brown@frost.com
HANGZHOU, China, December 15, 2014 /PRNewswire/ — China Jo-Jo Drugstores, Inc. (NASDAQ CM: CJJD) (the “Company” or “China Jo-Jo“), a leading China-based retail and wholesale distributor of pharmaceutical and health care products through its own online and retail pharmacies, today announce that it has completed the acquisition of Hangzhou Sanhao Grand Pharmacy Chain Co., Ltd. (“Sanhao Drugstores”), a Hangzhou–based pharmacy chain with 11 stores.
Founded in 2006, Sanhao Drugstores is a well-known local drugstore chain and owns 11 drugstores in Hangzhou. Among the 11 stores, four have the qualification of “Designated Medical Institutions for Social Health Insurance (“SHI”),” and four others have passed the qualification tests. SHI Program is China’s national health insurance plan aimed to provide universal health insurance coverage to Chinese citizens. Only pharmacies with SHI qualification can serve SHI participants, thus acquiring SHI qualification would substantially enhance a pharmacy’s revenue and profitability. For example, the sales related to SHI accounted for about 55% of China Jo-Jo’s total sales in fiscal 2014.
The Company plans to relocate or remodel the majority of the acquired pharmacies in the upcoming months. After the restructuring of Sanhao Drugstores, the management expects it to generate about RMB 30 million (or $4.8 million) revenue in the calendar year of 2015.
Mr. Lei Liu, Chairman of the Company, stated, “The synergistic acquisition of Sanhao Drugstores will increase our total store count to over 60, from our current level of 51 drugstores. We also set our eyes on some key geographic locations in Hangzhou which allow us to expand our store penetration. We believe the investment will bring satisfactory economic benefits to our shareholders in the coming years.”About China Jo-Jo Drugstores, Inc.
China Jo-Jo Drugstores, Inc., through its own retail drugstores, wholesale distributor and online pharmacy, is a leading retailer and wholesale distributor of pharmaceutical and health care products in China. As of September 30, 2014, the Company had 51 retail pharmacies in Hangzhou. The Company’s wholesale subsidiary not only supplies its retail stores, but also distributes drug and other health care products to other drugstores and drug vendors. The Company routinely posts important information on its corporate websites at www.jiuzhou-drugstore.com (Chinese) and www.chinajojodrugstores.com (English).
Forward Looking Statement
Statements in this press release regarding the Company that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements, including, but not limited to, financial guidance, are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as “believe,” “expect,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” “anticipate,” the negatives thereof, or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. It is routine for the Company’s internal projections and expectations to change as the quarter and year progresses, and therefore it should be clearly understood that the internal projections and beliefs upon which the Company bases its expectations may change. Although these expectations may change, the Company is under no obligation to inform you if they do. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of numerous factors, including the risks associated with the effect of changing economic conditions in the People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products. Readers are referred to the reports and documents filed from time to time by the Company with the Securities and Exchange Commission for a discussion of these and other important risk factors that could cause actual results to differ from those discussed in forward-looking statements.
Contacts
China Jo-Jo Drugstores, Inc.
Ming Zhao
Chief Financial Officer
Tel: (561) 372-5555
Email: frank.zhao@jojodrugstores.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-jo-jo-drugstores-completed-the-acquisition-of-hangzhou-sanhao-grand-pharmacy-300009574.html
Shanghai-based game development group also adds two experienced board members to strengthen corporate governance and development strategy
SHANGHAI, December 15, 2014 /PRNewswire/ — Virtuos, one of the world’s largest game developers specializing in 3D art and game development for consoles and mobile devices, today announced that it has secured a new series B round of funding from Shanghai-based Xuhui Venture Capital. At the same time, Virtuos welcomes two new board members as strategic advisors: Steven Chiang, former President of Games at Zynga, and Francois Candelon, Senior Partner for Technology, Media and Telecommunications and Managing Director at Boston Consulting Group.
With more than 1,000 staff spread across eight studios and offices worldwide, Virtuos offers a full range of services from 2D/3D artwork to full game development across multiple platforms. While the Virtuos management team retains a controlling interest in the company, this new round of investment will support the company’s strategy to continuously grow its expertise in the latest game development and art techniques. It will also allow the company to further develop its creative abilities, adding skilled talent and increasing its co-production capabilities, where the company invests resources alongside publishers to create new titles, such as the recently announced Fairy Fantasy for iOS and Android, which was co-produced with Chinese publisher Netease. Virtuos also plans to build tools that facilitate integration with client teams in order to offer higher value-added services to game publishers and developers worldwide.
The addition of Steven Chiang and Francois Candelon to the board of directors will greatly strengthen the company’s corporate governance at a time when it has stepped out of start-up mode and is focused on managing growth sustainably. Steven comes with 20 years’ experience in the games industry, having previously held top positions at Zynga and Electronic Arts, where he was responsible for managing game studios and development strategies. Francois is a practice leader at the Boston Consulting Group, where he specializes in Information Technology. He has been advising IT multinationals on strategies for growth and operational challenges for more than two decades.
“The investment by Xuhui Venture Capital is a great testament to our ongoing success and will strengthen our ability to continue investing in talent and tools as we develop into the preferred partner for publishers and developers worldwide,” said Virtuos Co-Founder and CEO, Gilles Langourieux. “In addition, bringing Steven and Francois onto the board will ensure we have the right expertise to manage growth sustainably, while Virtuos focuses on adding value to its clients in order to help them achieve more.”
Xuhui Venture Capital is an investment fund located in the Xuhui district of Shanghai, China, the same district chosen by other leading companies such as Tencent and Oriental Dreamworks as their base in Shanghai. The firm is a long-time partner of the government-supported start-up incubator where Virtuos was founded 10 years ago and has investment experience in IT and gaming companies, bringing valuable insight to Virtuos. Xuhui Government recognized Virtuos in 2014 with the title of ‘Top 30 Company Start-up from Xuhui District.’
Virtuos Resources:
About Virtuos
Virtuos is one of the largest game developers specializing in 3D art and game development for consoles and mobile devices. The company has studios and offices in Shanghai, Chengdu, Xian, Saigon, Vancouver, San Francisco, Paris and Tokyo, and employs more than 1,000 staff representing 15 nationalities. Virtuos’ clients include 15 of the top 20 digital entertainment companies worldwide as well as renowned independent studios. For more information, please refer to: www.virtuosgames.com.
Media Contact:
Emma Rennell
Racepoint Global
Phone: + 852 3111 9971
erennell@racepointglobal.com
Joyce Yin
Racepoint Global
Phone: + 86 10 6581 8586 Ext 602
jyin@racepointglobal.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/virtuos-closes-new-series-b-funding-round-to-sustain-growth-momentum-300009471.html
SYDNEY, December 15, 2014 /PRNewswire/ — Novogen Ltd (ASX: NRT, NASDAQ: NVGN) is an Australian/US biotechnology company that has developed a first-in-class experimental chemotherapeutic known as Cantrixil, which is due to enter a first-in-man clinical study in 2015.
The Company has posted a video on its website reporting on the status of this clinical trial program. The video can be accessed via its YouTube channel here: http://goo.gl/ljpl6M
Cantrixil is a unique development in chemotherapy, being the first cytotoxic chemotherapy to be developed specifically for injection into the body’s cavities. The peritoneal and pleural cavities are involved in a large proportion of cancers, and yet the vast majority of chemotherapies continue to be administered in a way that delivers chemotherapies to the cancer via the bloodstream.
Delivering the drug directly into the cavity where the cancer is spreading ensures cancer cells are exposed to levels of drug some hundreds of times greater than via the blood.
Cantrixil has been developed jointly by Novogen and Yale University and is owned by their joint-venture company, CanTx Inc.
Cantrixil is a construct of active drug candidate, TRXE-002, in a cyclodextrin shell. On injection into the cavity, the shell dissolves to release the active drug. Cantrixil has been designed to be non-irritant and to not be dose-limiting due to side-effects.
As Novogen and CanTx CEO, Dr. Graham Kelly, explains in the video, “The outstanding feature of Cantrixil is its ability to kill the full range of cancer cells within a tumour. If we are to make any meaningful progress in the survival prospects of patients with cancers such as those of the ovary, uterus, oesophagus, stomach, appendix, large bowel, pancreas and lung, then we have to find a way of killing the cancer stem cells that maintain the cancer.”
TRXE-002 is the first drug candidate to emerge from the Novogen super-benzopyran drug platform that for the first time kills all forms of cancer cells through a common mechanism. The platform does not rely on a targeted therapeutic approach of identifying a cancer stem cell market, a strategy that carries the risk of the cancer cell developing detours around the blocked target.
Dr. Kelly also explains how, in a world-first, Cantrixil has proven, in a stringent animal model of human ovarian cancer, to completely block cancer development.
Cantrixil is set to come into the clinic in Australian hospitals in the first instance, followed by US centres. The Phase 1 study will be enrolling patients with a variety of cancers that either have arisen in the abdomen or have metastasised there and which have become unresponsive to therapy.
To stay informed about the Novogen clinical program, readers are invited to sign up to receive the Company newsletters and press releases by visiting www.novogen.com or contacting Novogen directly.
About CanTx
CanTx Ltd is a private biotechnology company based in New Haven, Connecticut, and established as a joint venture between Novogen and Yale University. CanTx is dedicated to the development of anti-cancer drugs for the treatment of ovarian cancer.
About Novogen Limited
Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange (‘NRT’) and NASDAQ (‘NVGN’). The Novogen Group includes a New Haven CT — based joint venture company, CanTx Inc, with Yale University.
Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell’s cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.
Further information is available on the Company’s website, www.novogen.com.
For more information please contact:
Corporate Contact
Executive Chairman & CEO
Novogen Group
Graham.Kelly@novogen.com
+61 (0) 2 9472 4100
Media Enquiries
Operations Manager
Novogen Group
Cristyn.Humphreys@novogen.com
+61 (0) 2 9472 4111
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/novogen-provides-update-on-progress-of-cantrixil-into-the-clinic-300008930.html
BEIJING, December 15, 2014 /PRNewswire/ — Jumei International Holding Limited (NYSE: JMEI) (“Jumei” or the “Company”), China’s leading online retailer of beauty products, today announced that its board of directors has authorized a share repurchase program under which the Company may repurchase up to US$100 million of its shares over the next 12 months.
The Company’s proposed repurchases may be made from time to time on the open market at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. Jumei’s board of directors will review the share repurchase program periodically, and may authorize adjustment of its terms and size. The Company plans to fund repurchases from its existing cash balance.
Mr. Leo Ou Chen, chairman and founder of Jumei, commented, “The implementation of our share repurchase program reflects the confidence that our management have in Jumei’s growth prospects and operating fundamentals. This repurchase program reflects a commitment by our management to enhance value for our shareholders while retaining adequate flexibility for future growth.”
About Jumei International Holding Limited
Jumei (NYSE: JMEI) is China’s No. 1 online retailer of beauty products as measured by gross merchandise volume, with a market share of 22.1% in 2013, according to a commissioned research report by Frost & Sullivan. Jumei’s internet platform is a trusted destination for consumers to discover and purchase branded beauty products, fashionable apparel and other lifestyle products through the Company’s jumei.com website and mobile application. Leveraging its deep understanding of customer needs and preferences, as well as its strong merchandizing capabilities, Jumei has adopted multiple effective sales formats to encourage product purchases on its platform, including curated sales, online shopping mall and flash sales.
For investor and media inquiries, please contact:
Jumei International Holding Limited
Mr. Sterling Song
Investor Relations Director
Phone: +86-10-5676-6983
E-mail: kans@jumei.com
Christensen
In China
Mr. Christian Arnell
Phone: +86-10-5900-1548
E-mail: carnell@christensenir.com
In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
E–mail: lbergkamp@ChristensenIR.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/jumei-announces-100-million-share-repurchase-program-300009506.html
SHANGHAI, December 15, 2014 /PRNewswire/ — WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States, announced that it will open offices in Boston and San Francisco in early 2015. These new offices will give the company greater access to innovative companies in the world’s two leading biotech hubs, both as customers and as investments. In October, WuXi announced that it had opened an office in Israel to tap into the biotech community there. In addition, the company has U.S. facilities in St. Paul, Philadelphia, Atlanta, Plainsboro (NJ), and San Diego.
“Our vision is to enable anyone and any company to discover and develop healthcare products to benefit the world’s patients,” said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. “These new offices bring our comprehensive platform of integrated R&D services closer to where entrepreneurs are and where cutting-edge science is being done.”
About WuXi PharmaTech
WuXi PharmaTech (NYSE: WX) is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech’s services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.
For more information, please contact:
Ronald Aldridge
Director of Investor Relations
+1 (201) 585-2048
ron_aldridge@wuxiapptec.com
Aaron Shi
Director of Corporate Communications
+86-21-5046-4362
aaron_shi@wuxiapptec.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/wuxi-opening-offices-in-boston-and-san-francisco-300009394.html
WUHAN, China, December 15, 2014 /PRNewswire/ — Kingold Jewelry, Inc. (“Kingold” or “the Company”) (NASDAQ: KGJI), one of China’s leading manufacturers and designers of high quality 24-karat gold jewelry, ornaments and investment-oriented products, today announced that it and MLV & Co. LLC (“MLV”) mutually agreed to immediately terminate the previously announced At Market Issuance Sales Agreement pursuant to which the Company could have offered and sold up to $10,000,000 of shares of its common stock from time to time with MLV as sales agent (“ATM Facility”). The Company did not sell any shares of its common stock under the ATM Facility.
The Chairman of Kingold intends to schedule a meeting of its Board of Directors to review corporate strategy with a view towards enhancing stockholder value. The review process will be ongoing and is expected to define corporate goals that focus on increasing stockholder value, providing greater access to management, setting high standards of corporate governance, reviewing the role of professional advisors and providing investors with the appropriate level of information and transparency.
The Company’s management and its Board of Directors are proud of Kingold’s success at the operating level and look forward to seeing that success reflected in the Company’s stock performance.
About Kingold Jewelry, Inc.
Kingold Jewelry, Inc. (NASDAQ: KGJI), centrally located in Wuhan City, one of China’s largest cities, was founded in 2002 and today through a variable interest entity, or VIE, relationship with Wuhan Kingold Jewelry Company Limited, a corporation incorporated in the People’s Republic of China, is one of China’s leading designers and manufacturers of 24-karat gold jewelry, ornaments, and investment-oriented products. The Company sells both directly to retailers as well as through major distributors across China. Kingold has received numerous industry awards and has been a member of the Shanghai Gold Exchange since 2003. For more information, please visit www.kingoldjewelry.com.
Business Risks and Forward-Looking Statements
This press release contains forward-looking statements that are subject to the safe harbors created under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. You can identify these forward-looking statements by words such as “expects,” “believe,” “project,” “anticipate,” or similar expressions. The forward-looking statements in this release include statements regarding Kingold’s investor relations review and the timing of the implementation and the effects of such review. Readers are cautioned that actual results could differ materially from those expressed in any forward-looking statements. Forward-looking statements are subject to a number of risks, including those contained in Kingold’s SEC filings available at www.sec.gov, including Kingold’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. Kingold undertakes no obligation to update or revise any forward-looking statements for any reason.
Company Contact
Kingold Jewelry, Inc.
Bin Liu, CFO
Phone: +1-847-660-3498 (US) / +86-27-6569-4977 (China)
bl@kingoldjewelry.com
INVESTOR RELATIONS
The Equity Group Inc.
Katherine Yao, Associate
+86 10-6587-6435
kyao@equityny.com
Adam Prior, Senior Vice President
(212) 836-9606
aprior@equityny.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/kingold-jewelry-announces-termination-of-at-market-issuance-sales-agreement-300009501.html